These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 14628982)

  • 1. Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    Rapaport MH; Schneider LS; Dunner DL; Davies JT; Pitts CD
    J Clin Psychiatry; 2003 Sep; 64(9):1065-74. PubMed ID: 14628982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
    J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial.
    Rapaport MH; Lydiard RB; Pitts CD; Schaefer D; Bartolic EI; Iyengar M; Carfagno M; Lipschitz A
    J Clin Psychiatry; 2009 Jan; 70(1):46-57. PubMed ID: 19026248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.
    Golden RN; Nemeroff CB; McSorley P; Pitts CD; Dubé EM
    J Clin Psychiatry; 2002 Jul; 63(7):577-84. PubMed ID: 12143913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    Miner CM; Brown EB; Gonzales JS; Munir R
    J Clin Psychiatry; 2002 Mar; 63(3):232-40. PubMed ID: 11926723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
    Lepola U; Bergtholdt B; St Lambert J; Davy KL; Ruggiero L
    J Clin Psychiatry; 2004 Feb; 65(2):222-9. PubMed ID: 15003077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials.
    Dunner DL; Lipschitz A; Pitts CD; Davies JT
    Clin Ther; 2005 Dec; 27(12):1901-11. PubMed ID: 16507376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study.
    McIntyre A; Gendron A; McIntyre A
    Depress Anxiety; 2007; 24(7):487-94. PubMed ID: 17177199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression.
    Musselman DL; Somerset WI; Guo Y; Manatunga AK; Porter M; Penna S; Lewison B; Goodkin R; Lawson K; Lawson D; Evans DL; Nemeroff CB
    J Clin Psychiatry; 2006 Feb; 67(2):288-96. PubMed ID: 16566626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea.
    Higuchi T; Hong JP; Jung HY; Watanabe Y; Kunitomi T; Kamijima K
    Psychiatry Clin Neurosci; 2011 Dec; 65(7):655-63. PubMed ID: 21895859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    Weihs KL; Settle EC; Batey SR; Houser TL; Donahue RM; Ascher JA
    J Clin Psychiatry; 2000 Mar; 61(3):196-202. PubMed ID: 10817105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Kasper S; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2005 Aug; 21(8):1139-46. PubMed ID: 16083521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Baldwin DS; Cooper JA; Huusom AK; Hindmarch I
    Int Clin Psychopharmacol; 2006 May; 21(3):159-69. PubMed ID: 16528138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder.
    Sheehan DV; Burnham DB; Iyengar MK; Perera P;
    J Clin Psychiatry; 2005 Jan; 66(1):34-40. PubMed ID: 15669886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.